Halozyme Therapeutics Well-positioned to Execute Existing Strategy With Clear Line of Sight to 10 Approved Products With ENHANZE in 2025 and $1B of Royalty Rev in 2027 >HALO
Halozyme Therapeutics Well-positioned to Execute Existing Strategy With Clear Line of Sight to 10 Approved Products With ENHANZE in 2025 and $1B of Royalty Rev in 2027 >HALO
奥洛兹美医疗处于良好位置,具备清晰的视野,以在2025年与ENHANZE推出10款已批准产品的现有策略。并在2027年获得10亿美元的专利费营收。>HALO
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册